Study #2024-1705
A phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable stage III non-small cell lung cancer
MD Anderson Study Status
Enrolling
Treatment Agent
JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin, Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Description
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Carcinoma, Non-Small-Cell Lung
Study phase:
Phase II
Physician name:
Saumil Gandhi
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.